Prediction of in vivo drug-drug interactions from in vitro data:: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant

被引:113
作者
Brown, HS
Ito, K
Galetin, A
Houston, JB [1 ]
机构
[1] Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester M13 9PL, Lancs, England
[2] Hoshi Univ, Dept Clin Pharmacokinet, Tokyo 142, Japan
关键词
CYP2C9; CYP2D6; CYP3A4; drug-drug interactions; in vitro prediction;
D O I
10.1111/j.1365-2125.2005.02483.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims Success of the quantitative prediction of drug-drug interactions via inhibition of CYP-mediated metabolism from the inhibitor concentration at the enzyme active site ([I]) and the in vitro inhibition constant (K-i) is variable. The aim of this study was to examine the impact of the fraction of victim drug metabolized by a particular CYP (f(mCYP)) and the inhibitor absorption rate constant (k(a)) on prediction accuracy. Methods Drug-drug interaction studies involving inhibition of CYP2C9, CYP2D6 and CYP3A4 (n = 115) were investigated. Data on f(mCYP) for the probe substrates of each enzyme and k(a) values for the inhibitors were incorporated into in vivo predictions, alone or in combination, using either the maximum hepatic input or the average systemic plasma concentration as a surrogate for [I]. The success of prediction (AUC ratio predicted within twofold of in vivo value) was compared using nominal values of f(mCYP) = 1 and k(a) = 0.1 min(-1). Results The incorporation of f(mCYP) values into in vivo predictions using the hepatic input plasma concentration resulted in 84% of studies within twofold of in vivo value. The effect of k(a) values alone significantly reduced the number of over-predictions for CYP2D6 and CYP3A4; however, less precision was observed compared with the f(mCYP). The incorporation of both f(mCYP) and k(a) values resulted in 81% of studies within twofold of in vivo value. Conclusions The incorporation of substrate and inhibitor-related information, namely f(mCYP) and k(a), markedly improved prediction of 115 interaction studies with CYP2C9, CYP2D6 and CYP3A4 in comparison with [I]/K-i ratio alone.
引用
收藏
页码:508 / 518
页数:11
相关论文
共 40 条
[11]   FELODIPINE KINETICS IN HEALTHY-MEN [J].
EDGAR, B ;
REGARDH, CG ;
JOHNSSON, G ;
JOHANSSON, L ;
LUNDBORG, P ;
LOFBERG, I ;
RONN, O .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 38 (02) :205-211
[12]  
FRITZ S, 1987, J PHARMACOL EXP THER, V241, P615
[13]   CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions [J].
Galetin, A ;
Ito, K ;
Hallifax, D ;
Houston, JB .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 314 (01) :180-190
[14]   PHARMACOKINETICS OF THE NEWER BENZODIAZEPINES [J].
GARZONE, PD ;
KROBOTH, PD .
CLINICAL PHARMACOKINETICS, 1989, 16 (06) :337-364
[15]  
GREENBLATT DJ, 1977, J PHARMACOL EXP THER, V202, P365
[16]   PHARMACOKINETICS OF ITRACONAZOLE FOLLOWING ORAL-ADMINISTRATION TO NORMAL VOLUNTEERS [J].
HARDIN, TC ;
GRAYBILL, JR ;
FETCHICK, R ;
WOESTENBORGHS, R ;
RINALDI, MG ;
KUHN, JG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (09) :1310-1313
[17]   Role of itraconazole metabolites in CYP3A4 inhibition [J].
Isoherranen, N ;
Kunze, KL ;
Allen, KE ;
Nelson, WL ;
Thummel, KE .
DRUG METABOLISM AND DISPOSITION, 2004, 32 (10) :1121-1131
[18]  
Ito K, 1998, PHARMACOL REV, V50, P387
[19]   Database analyses for the prediction of in vivo drug-drug interactions from in vitro data [J].
Ito, K ;
Brown, HS ;
Houston, JB .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (04) :473-486
[20]   Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm [J].
Ito, K ;
Hallifax, D ;
Obach, RS ;
Houston, JB .
DRUG METABOLISM AND DISPOSITION, 2005, 33 (06) :837-844